S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
NASDAQ:OCUL

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$4.85
-0.28 (-5.46%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.83
$5.13
50-Day Range
$3.87
$6.27
52-Week Range
$2.57
$6.53
Volume
607,188 shs
Average Volume
1.21 million shs
Market Capitalization
$375.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
137.1% Upside
$11.50 Price Target
Short Interest
Bearish
5.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$161,777 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.03) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

354th out of 986 stocks

Pharmaceutical Preparations Industry

159th out of 477 stocks


OCUL stock logo

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

JMP Securities Keeps Their Buy Rating on Aura Biosciences Inc (AURA)
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Q4 2022 Ocular Therapeutix Inc Earnings Call
Why Shares of Ocular Therapeutix Jumped This Week
Berenberg Bank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Ocular Soars after Positive Interim Data
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings
11/08/2021
Today
3/23/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUL
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+137.1%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-71,040,000.00
Net Margins
-137.95%
Pretax Margin
-137.95%

Debt

Sales & Book Value

Annual Sales
$51.49 million
Book Value
$0.46 per share

Miscellaneous

Free Float
73,789,000
Market Cap
$375.92 million
Optionable
Optionable
Beta
1.28

Key Executives

  • Antony MattessichAntony Mattessich
    President, Chief Executive Officer & Director
  • Donald Notman
    Chief Financial Officer
  • Peter Jarrett
    Chief Scientific Officer
  • Rabia Gurses Ozden
    Chief Medical Officer
  • Karen-Leigh Edwards
    Senior Vice President-Technical Operations













OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year target prices for Ocular Therapeutix's stock. Their OCUL share price forecasts range from $10.00 to $14.00. On average, they predict the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 137.1% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2023?

Ocular Therapeutix's stock was trading at $2.81 at the beginning of the year. Since then, OCUL shares have increased by 72.6% and is now trading at $4.85.
View the best growth stocks for 2023 here
.

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,980,000 shares, an increase of 27.2% from the February 13th total of 3,130,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is currently 2.9 days.
View Ocular Therapeutix's Short Interest
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03. The biopharmaceutical company earned $12.15 million during the quarter, compared to analysts' expectations of $12.13 million. Ocular Therapeutix had a negative net margin of 137.95% and a negative trailing twelve-month return on equity of 127.95%. During the same period last year, the business earned ($0.17) EPS.

What ETFs hold Ocular Therapeutix's stock?
What guidance has Ocular Therapeutix issued on next quarter's earnings?

Ocular Therapeutix issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $69.98 million.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Summer Road LLC (7.95%), Opaleye Management Inc. (7.89%), Deltec Asset Management LLC (2.41%), Geode Capital Management LLC (1.83%), Emerald Advisers LLC (1.25%) and Emerald Mutual Fund Advisers Trust (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.85.

How much money does Ocular Therapeutix make?

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $375.92 million and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-71,040,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

The company employs 228 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 3/23/2023 by MarketBeat.com Staff